Clinical Trial Update: Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/Phase 2 study evaluating the diagnostic utility of the PET tracer F-18 Florbetapir in conjunction with MRI for peripheral nerve amyloidosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis

Drugs mentioned

• AMYVID (Florbetapir F-18)

Snippet

Sponsor: Mayo Clinic | Conditions: Amyloidosis | Phase 1, Phase 2 | Status: COMPLETED